Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.

Date publication

septembre 2007

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie

Tous les auteurs :
Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, Janicot H, Westeel V, Gameroff S, Genève J, Maraninchi D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/17761978

Résumé

This randomized, double-blind, placebo-controlled phase III study aimed to determine whether thalidomide prolongs survival of patients with extensive-disease small-cell lung cancer (SCLC).

Mots clés

Carcinoma, Small Cell, drug therapy, Disease-Free Survival, Double-Blind Method, Female, Humans, Lung Neoplasms, drug therapy, Male, Middle Aged, Proportional Hazards Models, Survival Rate, Thalidomide, therapeutic use

Référence

J. Clin. Oncol.. 2007 Sep;25(25):3945-51